COGNITION THERAPEUTICS INC (CGTX): Submission of Matters to a Vote of Security Holders
COGNITION THERAPEUTICS INC (CGTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001455365 0001455365 2026-06-17 2026-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report
How this was made
The 30-second read
Why it matters
The disclosure confirms director elections (Aaron Fletcher, Ph.D. and Lisa Ricciardi) and ratifies Ernst & Young LLP as independent auditor for fiscal 2026; it does not include new financial metrics, guidance, or material corporate actions.
Market read
This is a routine governance update; it is unlikely to drive trading decisions absent additional context from the proxy statement.
What to watch
Traders may still check the definitive proxy statement for any accompanying proposals or governance changes not captured in this brief 8-K summary.
Background
The company submitted an SEC Form 8-K under Item 5.07 summarizing final voting results from its June 17, 2026 Annual Meeting.
Ticker impact
CGTX filed an 8-K reporting Annual Meeting voting results, including election of Class II directors and ratification of Ernst & Young as auditor.
Likely minimal near-term impact; any move would be noise around governance headlines rather than fundamentals.
The filing only summarizes proxy vote outcomes (director elections, auditor ratification) without new operating, clinical, or capital-market information.
Market effects
None—no sector-wide regulatory, clinical, or competitive development is disclosed.
None indicated; this is company-specific proxy voting disclosure.
None—no cross-border deal, financing, or regulatory action is mentioned.
Counterpoint
Even routine votes can matter if they signal board/oversight changes, but this filing provides no qualitative rationale or strategic shift.
Key entities
- issuerCognition Therapeutics, Inc.
Subject of the SEC 8-K; reported Annual Meeting voting results under Item 5.07.
- auditorErnst & Young LLP
Ratified as the company’s independent registered public accounting firm for fiscal 2026.
- directorAaron Fletcher, Ph.D.
Elected to the Board of Directors as Class II director.
- director/executiveLisa Ricciardi
Elected as Class II director; also signed the 8-K as President and CEO.
